Complementary Antisense Oligonucleotide Treatment and Precision Sodium Channel Modulation for Early Onset SCN2A Developmental and Epileptic Encephalopathy: Emergency Use Case in a Preterm Infant with Refractory Status Epilepticus (P10-11.009)

Silvana Frizzo; M Wagner; Malin Zaddach; C. Nussbaum; Géza Berecki; Andreas Flemmer; Florian Heinen; Brian Spar; Martin Staudt; Moritz Tacke; Markus Wolff; Walid Fazeli; Steven Petrou; Marcio Souza; Ingo Borggraefe

doi:10.1212/wnl.0000000000215726

June 9, 2026Neurology

Complementary Antisense Oligonucleotide Treatment and Precision Sodium Channel Modulation for Early Onset SCN2A Developmental and Epileptic Encephalopathy: Emergency Use Case in a Preterm Infant with Refractory Status Epilepticus (P10-11.009)

View Full Paper

Ask AI

Bookmark

Share

Key Points

The report aims to describe the emergency use of ASO and sodium channel modulation in a case of SCN2A-DEE and refractory SE.
Emergency use of the antisense oligonucleotide (ASO), elsunersen,
Administration of the precision sodium channel modulator, relutrigine
Focus on a preterm infant diagnosed with SCN2A-DEE and SE.
Successful modulation of epilepsy symptoms in the preterm infant after treatment.
Significant reduction in frequency of seizures reported following ASO and relutrigine treatment.
Demonstration of a novel therapeutic pathway for SCN2A-DEE and refractory SE.

Implication

Case report demonstrates the use of ASO and sodium channel modulator to address SE in an infant, indicating new therapeutic strategies.

Abstract

This is a case report of the first complementary emergency use of the antisense oligonucleotide (ASO), elsunersen, and the precision sodium channel modulator, relutrigine, in an infant with severe early onset SCN2A developmental and epileptic encephalopathy (SCN2A-DEE) and refractory status epilepticus (SE).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Frizzo et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf34dfaef96ed7f055bca https://doi.org/10.1212/wnl.0000000000215726

View Full Paper

Ask AI

Bookmark

Share

Complementary Antisense Oligonucleotide Treatment and Precision Sodium Channel Modulation for Early Onset SCN2A Developmental and Epileptic Encephalopathy: Emergency Use Case in a Preterm Infant with Refractory Status Epilepticus (P10-11.009)

Key Points

Implication

Abstract

Discussion

Cite This Study

Complementary Antisense Oligonucleotide Treatment and Precision Sodium Channel Modulation for Early Onset SCN2A Developmental and Epileptic Encephalopathy: Emergency Use Case in a Preterm Infant with Refractory Status Epilepticus (P10-11.009)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading